A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

July 3, 2025

Primary Completion Date

February 18, 2030

Study Completion Date

February 24, 2030

Conditions
Castration-Resistant Prostatic CancerMetastasis
Interventions
DRUG

Docetaxel

Administered via Intravenous (IV) infusion at a specified dose on specified days

DRUG

Ifinatamab Deruxtecan

Administered via IV infusion at a specified dose on specified days

DRUG

MK-5684

Administered orally at a specified dose on specified days

DRUG

Abiraterone

Administered orally at a specified dose on specified days

DRUG

Enzalutamide

Administered orally at a specified dose on specified days

Trial Locations (35)

1023

RECRUITING

Auckland City Hospital ( Site 0831), Auckland

2109

RECRUITING

Macquarie University-MQ Health Clinical Trials Unit ( Site 0801), Macquarie University

11217

RECRUITING

Taipei Veterans General Hospital ( Site 0901), Taipei

20133

RECRUITING

Fondazione IRCCS Istituto Nazionale Dei Tumori ( Site 0431), Milan

25123

RECRUITING

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia ( Site 0432), Brescia

28034

RECRUITING

Hospital Universitario Ramon y Cajal ( Site 0620), Madrid

28041

RECRUITING

Hospital Universitario 12 de Octubre ( Site 0622), Madrid

40705

RECRUITING

Taichung Veterans General Hospital ( Site 0902), Taichung

69120

RECRUITING

NCT ( Site 0528), Heidelberg

2520598

RECRUITING

ONCOCENTRO APYS ( Site 0234), Viña del Mar

3109601

RECRUITING

Rambam Health Care Campus ( Site 0400), Haifa

3465584

RECRUITING

Clinica Universidad Catolica del Maule ( Site 0236), Talca

4941492

RECRUITING

Rabin Medical Center ( Site 0402), Petah Tikva

5265601

RECRUITING

Sheba Medical Center ( Site 0401), Ramat Gan

6423906

RECRUITING

Sourasky Medical Center ( Site 0403), Tel Aviv

8420383

RECRUITING

Bradfordhill ( Site 0231), Santiago

C1426ANZ

RECRUITING

Instituto Alexander Fleming ( Site 0202), Ciudad Autónoma de Buenos Aires

F5300COE

RECRUITING

Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0200), La Rioja

59062-000

RECRUITING

Liga Norte Riograndense Contra o Câncer ( Site 0271), Natal

90020-090

RECRUITING

Irmandade da Santa Casa de Misericórdia de Porto Alegre ( Site 0270), Porto Alegre

90035-001

RECRUITING

Hospital Moinhos de Vento ( Site 0278), Porto Alegre

15090-000

RECRUITING

Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0263), São José do Rio Preto

01221-020

RECRUITING

IPITEC ( Site 0275), São Paulo

03102-006

RECRUITING

IBCC - Instituto Brasileiro de Controle do Câncer ( Site 0269), São Paulo

07747

RECRUITING

Universitaetsklinikum Jena ( Site 0525), Jena

00168

RECRUITING

Fondazione Policlinico Universitario Agostino Gemelli ( Site 0433), Roma

6525 GA

RECRUITING

UMC St. Radboud ( Site 0679), Nijmegen

60-355

RECRUITING

Uniwersytecki Szpital Kliniczny w Poznaniu ( Site 0590), Poznan

02-781

RECRUITING

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 0586), Warsaw

80-214

RECRUITING

Uniwersyteckie Centrum Kliniczne ( Site 0588), Gdansk

75-581

RECRUITING

Szpital Wojewódzki im. M.Kopernika Oddział Onk. Klinicznej z Pododdziałem Chemioterapii Jednodniowej ( Site 0587), Koszalin

05505

RECRUITING

Asan Medical Center ( Site 0925), Songpagu

03722

ACTIVE_NOT_RECRUITING

Severance Hospital Yonsei University Health System ( Site 0924), Seoul

06351

RECRUITING

Samsung Medical Center ( Site 0926), Seoul

SM3 5PT

RECRUITING

Royal Marsden Hospital (Sutton) ( Site 0741), London

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Daiichi Sankyo

INDUSTRY

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT06863272 - A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) | Biotech Hunter | Biotech Hunter